Abstract:Liver cancer is one of the leading causes of death motivating scientists worldwide to synthesize novel therapeutics. Ru(II)-polypyridyl complexes are extensively studied for possible therapeutic and cellular applications due to their tunable coordination chemistry, structural diversity, ligand-exchange kinetics, accessible redox states, and rich photophysical or photochemical properties. Herein, we have synthesized a series of Ru(II) polypyridyl complexes [RuII(N^N) 2 (ox)] ( 1 - 3 ), where ox is oxalate (C2O42-), N^N is 1,10-phenanthroline (phen) ( 1 ), dipyrido[3,2-d:2',3'-f]quinoxaline (dpq) ( 2 ), and dipyrido[3,2,-a:2',3'-c]phenazine (dppz) ( 3 ). The oxalate (ox 2- ) was opted as a bioactive dioxo ligand to prevent hydrolysis in aqueous media, thereby increasing the stability of the Ru(II)-polypyridyl complexes in physiological media. We thoroughly characterized all the complexes using ESI-MS, FT-IR, UV-vis, and 1H NMR spectroscopy and other physicochemical methods. The complexes were stable under physiological conditions and under low-energy green LED light (λirr= 530 nm). However, the photoirradiation of complexes resulted in the efficient generation of singlet oxygen ( 1 O 2 ) as a major reactive oxygen species (ROS). The role of extended aromatic conjugation of the N^N-donor ligands in the complexes was demonstrated on their binding propensities with CT-DNA and bovine serum albumin (BSA). Both DNA intercalation and groove binding are evidenced, while tryptophan (Trp) and tyrosine (Tyr) binding preferences are revealed from the synchronous fluorescence spectral (SFS) of BSA. The cytotoxic profiling of the complexes performed on hepatocellular carcinoma cells (HepG2) in the dark and in the presence of green light indicated their dose-dependent cytotoxicity. The [Ru II (N^N)2(ox)] complexes exhibit enhanced photocytotoxicity mediated by efficient generation of cytotoxic 1 O 2 and DNA interaction. All the complexes internalize to the HepG2 liver cancer cells efficiently and localize to the cytoplasm and nucleus. The complexes exhibited potent anti-proliferative, anti-clonogenic, and anti-migratory effects on the cancer cells, suggesting their potential promise for therapeutic applications.

A HCBP1 Peptide Conjugated Ruthenium Complex for Targeted Therapy of Hepatoma.

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Cyclic Ruthenium-Peptide Conjugates as Integrin-Targeting Phototherapeutic Prodrugs for the Treatment of Brain Tumors

Ruthenium(II) Polypyridyl Complexes: Cellular Uptake, Cell Image and Apoptosis of HeLa Cancer Cells Induced by Double Targets

Designing biotin-human serum albumin nanoparticles to enhance the targeting ability of binuclear ruthenium(III) compound

Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes

The ruthenium complex assists in nuclear targeting and selective killing of tumor cells

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Exploring the potential of ruthenium(ii)–phosphine–mercapto complexes as new anticancer agents

A Synthetic Peptide Mediated Active Targeting of Cisplatin Liposomes to Tie2 Expressing Cells.

Towards Selective Delivery of a Ruthenium(II) Polypyridyl Complex‐Containing Bombesin Conjugate into Cancer Cells

Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.

Investigation of SP94 Peptide As a Specific Probe for Hepatocellular Carcinoma Imaging and Therapy

Design, synthesis, and in vitro antitumor activity of a transferrin receptor‐targeted peptide–doxorubicin conjugate

Targeting Β-Catenin and PD-L1 Simultaneously by a Racemic Supramolecular Peptide for the Potent Immunotherapy of Hepatocellular Carcinoma.

Photocytotoxic Kinetically Stable Ruthenium(II)-N,N-donor Polypyridyl Complexes of Oxalate for Anticancer Activity Against HepG2 Liver Cancer Cells

Hepatocyte-targeting and Tumor Microenvironment-Responsive Liposomes for Enhanced Anti-Hepatocarcinoma Efficacy.

Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery

A dual-targeting ruthenium nanodrug that inhibits primary tumor growth and lung metastasis via the PARP/ATM pathway

Ruthenium(ii)-Arene Complex Triggers Immunogenic Ferroptosis for Reversing Drug Resistance

Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands